No phaseCompleted

Pasteurized Akkermansia Massiliensis LWHK0003 Supplementation in Patients With MASLD

Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials

Sponsor
National Taiwan University Hospital (Academic or other)
Enrollment
43 enrolled
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Pasteurized Akkermansia massiliensis LWHK0003; Placebo
Ages
adults, older adults
Registry
NCT06873165

Full record on ClinicalTrials.gov

From the registry

This randomized, double-blind, placebo-controlled phase I/II clinical trial evaluated the safety and potential efficacy of pasteurized Akkermansia massiliensis LWHK0003 in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants were randomly assigned to receive placebo or one of three doses of pasteurized A. massiliensis LWHK0003 (10⁹, 10¹⁰ or 10¹¹ pre-pasteurization colony-forming unit equivalents per day) for 12 weeks. Clinical assessments included liver steatosis and stiffness measured by FibroScan, glucose and lipid metabolic parameters, anthropometric measurements, blood pressure, safety evaluations and gut microbiota composition. Participants attended scheduled clinical visits every four weeks during the intervention and underwent a post-intervention follow-up assessment at week 16. The study aimed to evaluate the safety and preliminary clinical effects of pasteurized A. massiliensis LWHK0003 as a potential microbiome-based intervention for MASLD.

Primary outcomes

  • Change in Controlled Attenuation Parameter (CAP)
  • Change in Liver Stiffness Measurement (LSM)

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started